These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 18391625

  • 1. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
    Prenen H, Kimpe M, Nuyts S.
    Curr Opin Oncol; 2008 May; 20(3):270-4. PubMed ID: 18391625
    [Abstract] [Full Text] [Related]

  • 2. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Vattemi E, Graiff C, Sava T, Pedersini R, Caldara A, Mandarà M.
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
    [Abstract] [Full Text] [Related]

  • 3. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 Jun 10; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
    Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F.
    Oral Oncol; 2007 Sep 10; 43(8):729-34. PubMed ID: 17350323
    [Abstract] [Full Text] [Related]

  • 6. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R, Wilcken N, Shannon J.
    Aust Fam Physician; 2008 Sep 10; 37(1-2):45-9. PubMed ID: 18239753
    [Abstract] [Full Text] [Related]

  • 7. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Kim R, Toge T.
    Surg Today; 2004 Sep 10; 34(4):293-303. PubMed ID: 15052442
    [Abstract] [Full Text] [Related]

  • 8. Combining molecular therapeutics with radiotherapy for head and neck cancer.
    Riesterer O, Milas L, Ang KK.
    J Surg Oncol; 2008 Jun 15; 97(8):708-11. PubMed ID: 18493923
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S, Schiller JH.
    Crit Rev Oncol Hematol; 2007 May 15; 62(2):93-104. PubMed ID: 17306557
    [Abstract] [Full Text] [Related]

  • 11. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 12. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Dec 15; 7(12):4156-63. PubMed ID: 11751516
    [Abstract] [Full Text] [Related]

  • 13. Targeted cancer therapy: promise and reality.
    Klein S, Levitzki A.
    Adv Cancer Res; 2007 Dec 15; 97():295-319. PubMed ID: 17419951
    [Abstract] [Full Text] [Related]

  • 14. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D, Farrow B, Berger DH.
    Surg Oncol Clin N Am; 2008 Apr 15; 17(2):357-76, ix. PubMed ID: 18375357
    [Abstract] [Full Text] [Related]

  • 15. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S, Zakkouri FZ, Aitelhaj M, Mesmoudi M, Boutayeb A, Boutayeb W, Mrabti H, Errihani H.
    Pathol Biol (Paris); 2012 Aug 15; 60(4):229-33. PubMed ID: 22743095
    [Abstract] [Full Text] [Related]

  • 16. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 17. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A, Crombet T, González G.
    Ann Med; 2003 Mar 01; 35(5):327-36. PubMed ID: 12952019
    [Abstract] [Full Text] [Related]

  • 18. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
    Surakanti SG, Agulnik M.
    Semin Oncol; 2008 Jun 01; 35(3):309-19. PubMed ID: 18544445
    [Abstract] [Full Text] [Related]

  • 19. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
    Azim HA, Ganti AK.
    Cancer Treat Rev; 2006 Dec 01; 32(8):630-6. PubMed ID: 17034953
    [Abstract] [Full Text] [Related]

  • 20. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A.
    Head Neck; 2008 Jun 01; 30(6):800-9. PubMed ID: 18429007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.